VSTM Verastem (VSTM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001526119
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
103
13F, latest reported quarter
What the filings say about VSTM
Insiders, 180 days
-$490.5K net sold
2 sellers · 38% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$353.0K
1 notice
Verastem insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Verastem, Inc. insiders sold a net $490.5K of stock across 160 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 36 earlier Form 4 trades (code P or S) here by this insider (36 sales), the last on Sep 21, 2026.
- The trade is 2.1% of the 123,781 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Calkins Daniel sold about $20.5K of VSTM under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.Context
- 57 earlier Form 4 trades (code P or S) here by this insider (57 sales), the last on Aug 3, 2026.
- The trade is 6.8% of the 652,712 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Paterson Dan sold about $353.0K of VSTM under a 10b5-1 plan on Oct 1, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.Context
- 35 earlier Form 4 trades (code P or S) here by this insider (35 sales), the last on Jun 22, 2026.
- The trade is 0.0% of the 118,014 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Calkins Daniel sold about $424 of VSTM under a 10b5-1 plan on Sep 21, 2026; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.Context
- 56 earlier Form 4 trades (code P or S) here by this insider (56 sales), the last on Jun 22, 2026.
- The trade is 0.2% of the 589,940 shares held after it.
- No other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Paterson Dan sold about $7.6K of VSTM on Aug 3, 2026; 103 funds added in the latest 13F quarter.Context
- 55 earlier Form 4 trades (code P or S) here by this insider (55 sales), the last on May 4, 2026.
- The trade is 3.5% of the 591,242 shares held after it.
- 1 other insider sold within 30 days.
- 103 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Paterson Dan sold about $87.2K of VSTM on Jun 22, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 103 funds added in the latest 13F quarter.160 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$490.5K over 180 days
-$381.5K over 90 days
below 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
103 funds bought in last quarter
more than 70% of Pharma & Biotech
Revenue
+209.1% year over year
more than 90% of Pharma & Biotech
Margin
-677.6% net margin
below 81% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
18.7% of the float short (float per yahoo 2026-10-26) · 7.0 days to cover · settled 2026-09-30
more than 89% of Pharma & Biotech
What changed in the last 30 days
Oct 2President and CEO Paterson Dan sold $353.0K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Chief Financial Officer Calkins Daniel sold $20.5K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer, Director Dan Paterson filed to sell $353.0K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch VSTM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+29.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns VSTM: institutional holders (13F)
13F holdings, latest reported quarter
9,192,447 sh
$35.1M
7,169,640 sh
$27.4M
7,024,000 sh
$26.8M
6,699,254 sh
$25.6M
6,635,793 sh
$25.3M
Congress trades in VSTM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
VSTM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Dan Paterson
Filed 2026-10-01
$353.0K
Gagnon Robert E.
Filed 2026-07-23
$188.0K
Gagnon Robert E.
Filed 2026-06-25
$90.5K
Dan Paterson
Filed 2026-06-22
$87.2K
VSTM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Etf
$1.9M position · as of 2026-07-31
1.9%
iShares Genomics Immunology and Healthcare ETF
$1.0M position · as of 2026-07-31
0.5%
Franklin Biotechnology Discovery Fund
$2.3M position · as of 2026-07-31
0.2%
VANGUARD MARKET NEUTRAL FUND
$1.1M position · as of 2026-06-30
0.2%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$187.4K position · as of 2026-07-31
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
$667.9K position · as of 2026-07-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
13 registered trials, 10 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
8
Phase 2
6 active
1
Phase 3
1 active
4
Multi-phase
3 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $490.5K sold by insiders over 180 days, 103 funds added last quarter, $353.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
VSTM financials
Revenue growth
+209.1%
XBRL, annual
Net margin
-677.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$87.5M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM VSTM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $2.6M |
| FY Dec 2022 | $2.6M |
| FY Dec 2021 | $2.1M |
| Jun 2026 | $40.1M |
| Mar 2026 | $18.7M |
| Dec 2025 | $17.5M |
| Sep 2025 | $11.2M |
| Jun 2025 | $2.1M |
| Mar 2025 | n/a |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-231.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM VSTM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -3,365% |
| FY Dec 2022 | -2,843% |
| FY Dec 2021 | -3,468% |
| Jun 2026 | -86.5% |
| Mar 2026 | -196.0% |
| Dec 2025 | -187.7% |
| Sep 2025 | -876.3% |
| Jun 2025 | -1,214% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$162.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM VSTM
| FY Dec 2025 | -$137.5M |
| FY Dec 2024 | -$104.8M |
| FY Dec 2023 | -$86.7M |
| FY Dec 2022 | -$63.9M |
| FY Dec 2021 | -$53.7M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$25.1M |
| Sep 2024 | -$23.8M |
At each fiscal year end
Single quarter
Debt to equity
0.81x
LongTermDebt as filed 2024-12-31 (18 months older than the period end) (includes the current portion); equity 2026-06-30
Debt to equity VSTM
| FY Dec 2025 | 0.71x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.70x |
| FY Dec 2022 | 0.52x |
| FY Dec 2021 | 0.41x |
| Jun 2026 | 0.81x |
| Mar 2026 | 0.50x |
| Dec 2025 | 0.71x |
| Sep 2025 | n/a |
| Jun 2025 | 1.13x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 3.66x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.98x
TTM operating cash flow over LongTermDebt as filed 2024-12-31 (18 months older than the period end) (includes the current portion)
Cash flow to debt VSTM
| FY Dec 2025 | -3.38x |
| FY Dec 2024 | -2.57x |
| FY Dec 2023 | -2.16x |
| FY Dec 2022 | -2.60x |
| FY Dec 2021 | -1.50x |
| Jun 2026 | -3.98x |
| Mar 2026 | -3.71x |
| Dec 2025 | -3.38x |
| Sep 2025 | -3.26x |
| Jun 2025 | -2.95x |
| Mar 2025 | -2.83x |
| Dec 2024 | -2.57x |
| Sep 2024 | -2.70x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-471.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity VSTM
| FY Dec 2025 | -1,480% |
| FY Dec 2024 | -917.4% |
| FY Dec 2023 | -166.8% |
| FY Dec 2022 | -109.4% |
| FY Dec 2021 | -70.2% |
| Jun 2026 | -471.2% |
| Mar 2026 | -786.2% |
| Dec 2025 | -1,480% |
| Sep 2025 | n/a |
| Jun 2025 | -606.7% |
| Mar 2025 | n/a |
| Dec 2024 | -917.4% |
| Sep 2024 | -198.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-100.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets VSTM
| FY Dec 2025 | -120.4% |
| FY Dec 2024 | -104.0% |
| FY Dec 2023 | -71.4% |
| FY Dec 2022 | -72.5% |
| FY Dec 2021 | -54.1% |
| Jun 2026 | -100.7% |
| Mar 2026 | -107.9% |
| Dec 2025 | -120.4% |
| Sep 2025 | -159.0% |
| Jun 2025 | -110.3% |
| Mar 2025 | -116.7% |
| Dec 2024 | -104.0% |
| Sep 2024 | -61.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital VSTM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-116.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed VSTM
| FY Dec 2025 | -139.0% |
| FY Dec 2024 | -118.6% |
| FY Dec 2023 | -93.6% |
| FY Dec 2022 | -89.2% |
| FY Dec 2021 | -54.0% |
| Jun 2026 | -116.5% |
| Mar 2026 | -132.9% |
| Dec 2025 | -139.0% |
| Sep 2025 | -155.5% |
| Jun 2025 | -141.5% |
| Mar 2025 | -135.9% |
| Dec 2024 | -118.6% |
| Sep 2024 | -94.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing VSTM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$819.1M
market value at close 2026-10-27 on 2026-08-03 shares, plus LongTermDebt as filed 2024-12-31 (18 months older than the period end) (includes the current portion), minus cash 2026-06-30
Enterprise value VSTM
| FY Dec 2025 | $351.2M |
| FY Dec 2024 | $182.0M |
| FY Dec 2023 | $167.9M |
| FY Dec 2022 | $958.0M |
| FY Dec 2021 | $4.5B |
| Jun 2026 | $240.0M |
| Mar 2026 | $340.7M |
| Dec 2025 | $351.2M |
| Sep 2025 | $446.5M |
| Jun 2025 | $104.4M |
| Mar 2025 | $233.6M |
| Dec 2024 | $182.0M |
| Sep 2024 | $47.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-17.7%
TTM free cash flow over market value at close 2026-10-27
FCF yield VSTM
| FY Dec 2025 | -26.7% |
| FY Dec 2024 | -45.5% |
| FY Dec 2023 | -42.1% |
| FY Dec 2022 | -6.3% |
| FY Dec 2021 | -1.2% |
| Jun 2026 | -48.3% |
| Mar 2026 | -32.4% |
| Dec 2025 | -26.7% |
| Sep 2025 | -24.4% |
| Jun 2025 | -52.7% |
| Mar 2025 | -37.1% |
| Dec 2024 | -45.5% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing VSTM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $30.9M | $10.0M | n/a | $2.6M |
| Operating income | -$170.1M | -$115.0M | -$92.1M | -$72.9M |
| Net income | -$209.5M | -$130.6M | -$87.4M | -$73.8M |
| EPS (diluted) | -3.02 | -3.66 | -3.96 | -4.57 |
| Operating cash flow | -$137.5M | -$104.8M | -$86.5M | -$63.7M |
| Cash | $205.0M | $88.8M | $77.9M | $74.9M |
| Long-term debt | n/a | $40.7M | $40.1M | $24.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
VSTM Stock Sonar score 6/7 axes
Find similar shapesCompareVSTM ranks highest on growth (90th percentile) and institutional and government (70th), and lowest on profitability (18th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
VSTM filings, in plain words
Are Verastem insiders buying or selling VSTM?
In the 180 days to 2026-10-28, Verastem insiders were net sellers, a net $490.5K across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of VSTM?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $353.0K of stock; the latest, by Dan Paterson, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-28, Verastem insiders were net sellers of VSTM, a net $490.5K across purchases and sales reported on Form 4 by 2 sellers. 38% of the 8 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $353.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
